Electra Therapeutics Inc.

ETRA

NASDAQHealthcareMedical - Pharmaceuticals

在 GoAI 中打开

前收盘价

US$8.94

+US$0.33 · +3.83%

10月14日 16:00 ET

公司概况

公司网站

Electra Therapeutics, Inc. is a clinical stage biotechnology company. It is engaged in therapies against novel targets for diseases in immunology and cancer. The company was founded by Adam Rosenthal on October 11, 2018 and is headquartered in South San Francisco, CA.

行业: Medical - Pharmaceuticals
部门: Healthcare
总部: US
首席执行官: Quehuong Dong
上市以来: 2026年9月18日
雇员: 46

市场位置

日内区间

当前US$8.94

US$8.50US$9.4675

52周区间

当前US$8.94

US$8.50US$15.50

开盘价: US$8.69
前收盘价: US$8.61
成交量: 52.11万; 0.61× 平均值
平均成交量: 85.39万; 日均成交量
市值: 1.9亿 USD
贝塔: 0; 市场参考 1
50天平均值: US$10.8195; 低于平均水平-17.37%
200天平均值: US$10.8195; 低于平均水平-17.37%

分析师评级

第三方分析师预期可能变化，并非 GoAI 建议。

分析师目标价

平均目标

US$32.00

上涨空间 257.94%

过去 12 个月12个月预测最高：US$32.00平均的：US$32.00最低：US$32.00

ETRA 消息

defenseworld.net2026年9月24日

Electra Therapeutics (NASDAQ:ETRA) Director Carl Gordon Acquires 1,333,333 Shares of Stock

Electra Therapeutics, Inc. (NASDAQ: ETRA - Get Free Report) Director Carl Gordon bought 1,333,333 shares of the company's stock in a transaction that occurred on Monday, September 21st. The stock was purchased at an…

阅读源码

defenseworld.net2026年9月24日

Electra Therapeutics (NASDAQ:ETRA) Director Orbimed Advisors Llc Purchases 1,333,333 Shares

Electra Therapeutics, Inc. (NASDAQ: ETRA - Get Free Report) Director Orbimed Advisors Llc bought 1,333,333 shares of the business's stock in a transaction on Monday, September 21st. The shares were acquired at an average…

阅读源码

globenewswire.com2026年9月19日

Kinzey Capital Management: Electra Sets Nasdaq IPO Terms

Kinzey Capital Management, based in Singapore, runs discretionary multi-asset portfolios serving private clients, corporates, families and foundations.

阅读源码

globenewswire.com2026年9月17日

Electra Therapeutics Announces Pricing of Upsized $350.0 Million Initial Public Offering

SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Electra Therapeutics, Inc., a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of…

阅读源码

reuters.com2026年9月14日

Electra Therapeutics targets $977.6 million valuation in US IPO

Drug developer Electra Therapeutics is targeting a valuation of up to $977.6 million in its U.S. initial public offering, according ‌to a filing on Monday, extending a comeback in biotech listings this year.

阅读源码